Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (825)	2/7/2002 10:39:23 AM
From: keokalani'nui	Read Replies (1) \| Respond to of 834

Actelion says Tracleer fails an CHF trial objective ZURICH, Feb 7 (Reuters) - Bio technology company Actelion said on Thursday that its Tracleer drug did not meet a primary efficacy objective in a phase III trial in chronic heart failure (CHF). As a consequence, its partner Genentech (NYSE:DNA - news) cannot exercise a December 2000 option to become a co-promotion partner for Tracleer. The Swiss firm said Tracleer, or Bosentan, failed to meet statistical significance in two pre-defined primary endpoints of risk reduction in time to death or hospitalisation, and improvement in clinical status at nine months of treatment. see also: Message 17026149